
Quick Takes, COVID-19 edition: A roundup of news, notes and notions from the NeuGroup Network. Strategic Acquistions: Waiting for Small Biotechs to Adjust to Lower ValuesHere’s some post-meeting follow-up from a treasurer in the biotech industry on his expectations for a “resetting of asset prices” and opportunities for strategic acquisitions as markets gyrate. “I would characterize it as an emerging opportunity. So far, you have had price adjustments (lower stock prices) for smaller biotechs. But you need two parties to…